Saturday 17 October 2026
Export NSRX’s income statement to Excel — free account
Nasus Pharma Ltd.
NSRX Healthcare Drug Manufacturers General
Insiders bought in the last twelve months.
3.18
0.01
+0.32%
Follow NSRX
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Current Ratio |
0.10 | 0.12 | 2.24 |
Net Debt/EBITDA |
(1.96) | (1.38) | 0.26 |
Debt/Assets |
553.38% | 251.32% | 0.00% |
Debt/Equity |
(0.65) | (0.56) | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.98 | 0.43 | 0.84 |
Capex/Depreciation |
— | — | 0.00 |
Interest Coverage |
(23.41) | (37.17) | 62.87 |
| 0.00% | 43.72% | 2,637.84% | |
| 0.00% | (263.91%) | (204.72%) | |
ROIC |
0.00% | 0.00% | (207.52%) |
Return on Tangible Assets |
27.68% | 44.12% | (216.41%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.15) | (0.09) | (0.62) |
Cash per Share |
0.03 | 0.04 | 0.16 |
Shareholders Equity per Share |
(0.55) | (0.46) | 0.35 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(0.55) | (0.46) | 0.35 |
Free Cash Flow |
(1.03) | (0.66) | (4.93) |
Working Capital |
(3.80) | (3.47) | 2.69 |
Capital Expenditures |
— | — | (0.01) |
Net Current Asset Value |
(3.80) | (3.47) | 2.62 |
| Other line items | |||
Quick Ratio |
0.05 | 0.08 | 0.60 |
Depreciation/Fixed assets |
— | — | 0.00 |
Cash ROIC |
91.06% | 60.51% | (121.51%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.15) | (0.09) | (0.61) |
Capex per Share |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.65 | 0.74 |
Average Assets |
— | 0.58 | 2.86 |
Average Common Equity |
— | (3.50) | (0.22) |
Capex to Sales |
— | — | 0.00 |
Columns are period end dates